2024 Volume 39 Issue 2 Pages 145-151
A 69－year－old man with a two-year history of having a pigmented lesion on his head developed a bleeding mass at the same site. After a skin biopsy was performed, he was diagnosed with malignant melanoma and subsequently referred to our hospital. Image examinations revealed brain and lung metastases. The primary and metastatic brain tumors were surgically resected. The BRAF mutation testing result was negative. Therefore, he was administered nivolumab monotherapy, which provided a partial response, as the lung metastases decreased in size. At the patient’s request, however, nivolumab was discontinued after 46 doses were administered. Two years passed since nivolumab discontinuation, with no increase in the lung metastases size or appearance of new metastases. This case highlights the lack of definitive guidelines on the optimal duration for treatment with immune checkpoint inhibitors. Here, we report on the duration of immune checkpoint inhibitor administration, with a review of relevant literature.[Skin Cancer (Japan) 2024 ; 39 : 145－151]
